Rational approaches to the treatment of patients with overweight and obesity: a cardiologist’s view

The objective is to evaluate various interventions for obesity in terms of their impact on life expectancy and the development of cardiovascular complications. When determining the degree of cardiovascular risk in patients suffering from obesity, one should rely not only on body mass index (BMI), but also on other data, namely, the presence of visceral obesity, metabolic disorders and/or cardiovascular diseases, type 2 diabetes mellitus. The review assesses drug and non-drug treatments for obesity, as well as bariatric surgery. GLP-1 agonist drugs and bariatric surgery, despite a significant reduction in body weight, showed the least impact on life expectancy and the development of cardiovascular diseases and complications. Moreover, they are expensive to use and have side effects. Indications for bariatric surgery should be significantly limited. Bariatric surgery is most indicated for people with type 2 diabetes and/or cardiovascular diseases when they cannot be corrected with medication and non-medicinal means. Based on the available data, the Mediterranean diet, brisk walking, and metformin, despite a slower and more moderate weight loss, have the best effect on the prognosis in patients suffering from obesity. Metformin therapy should be added to the treatment of patients suffering from obesity in combination with metabolic disorders and cardiovascular diseases. In this case, one should not remain on the initial doses, but individually select doses depending on the patient’s BMI.

1. Neeland I, Ross R, Després J, et al; International Atherosclerosis Society; International Chair on Cardiometabolic Risk Working Group on Visceral Obesity. Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement. Lancet Diabetes Endocrinol 2019;7(9):715-25. DOI:10.1016/S2213-8587(19)30084-1.

2. Neeland IJ, Poirier P, Després J. Cardiovascular and Metabolic Heterogeneity of Obesity: Clinical Challenges and Implications for Management. Circulation. 2018;137(13):1391-406. DOI:10.1161/CIRCULATIONAHA.117.029617.

3. Powell-Wiley TM, Poirier P, Burke L, et al; American Heart Association Council on Lifestyle and Cardiometabolic Health; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Epidemiology and Prevention; and Stroke Council. Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation. 2021;143(21):e984-e1010. DOI:10.1161/CIR.0000000000000973.

4. Chumakova GA, Kuznetsova TYu, Druzhilov MA, Gritsenko OV. Metabolic health of the population: a modern view of the problem and solutions. Russian Journal of Cardiology. 2024;29(5):5896. (In Russ.) DOI:10.15829/1560-4071-2024-5896.

5. Boone SС, van Smeden M, Rosendaal FR, et al. Evaluation of the Value of Waist Circumference and Metabolomics in the Estimation of Visceral Adipose Tissue. Am J Epidemiol. 2022;191(5):886-99. DOI:10.1093/aje/kwab298.

6. Omura-Ohata Y, Son C, Makino H, et al. Efficacy of visceral fat estimation by dual bioelectrical impedance analysis in detecting cardiovascular risk factors in patients with type 2 diabetes. Cardiovasc Diabetol. 2019;18(1):137. DOI:10.1186/s12933-019-0941-y.

7. Gómez-Ambrosi J, González-Crespo I, Catalán V, et al. Clinical usefulness of abdominal bioimpedance (ViScan) in the determination of visceral fat and its application in the diagnosis and management of obesity and its comorbidities. Clin Nutr. 2018;37(2):580-9. DOI:10.1016/j.clnu.2017.01.010.

8. Okorokov PL, Vasyukova OV, Vorontsov AV. The methods for the characteristic of adipose tissue in the organism and their clinical significance. Problems of Endocrinology. 2014;60:53-8. (In Russ.) DOI:10.14341/probl201460353-58.

9. Miklishanskaya SV, Zolozova EA, Safiullina AA, Mazur NA. Visceral obesity in patients with different body mass indices. Therapist. 2020;8:66-70. (In Russ.) DOI:10.26295/OS.2020.19.39.011.

10. Salmón-Gómez L, Catalán V, Frühbeck G, Gómez-Ambrosi J. Relevance of body composition in phenotyping the obesities. Rev Endocr Metab Disord. 2023;24(5):809-23. DOI:10.1007/s11154-023-09796-3.

11. Samorodskaya IV, Bolotova EV, Boytsov SA. Current issues of obesity classification. Cardiovascular Therapy and Prevention. 2015;14:103-10. (In Russ.) DOI:10.15829/1728-8800-2015-4-103-110.

12. Visseren FLJ, Mach F, Smulders YM, et al.; ESC National Cardiac Societies; ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227-337. DOI:10.1093/eurheartj/ehab484.

13. Boytsov SA, Pogosova NV, Ansheles AA, et al. Cardiovascular prevention. 2022. Russian national guidelines. Russian Journal of Cardiology. 2023;28(5):5452. (In Russ.) DOI:10.15829/1560-4071-2023-5452.

14. Drapkina OM, Samorodskaya IV, Starinskaya MA, et al. Obesity: assessment and tactics of patient management. Collective monograph. Moscow: Federal State Budgetary Institution "NMRC TPM" of the Ministry of Health of the Russian Federation; OOO "Silitseya-Polygraf". 2021. (In Russ.).

15. Drapkina OM, Lopatin YM, Petrov VI, et al. Diagnostics, treatment, prevention of obesity and associated diseases. National clinical guidelines. St. Petersburg, 2017. (In Russ.)

16. Hall ME, Cohen JB, Ard JD, et al.; American Heart Association Council on Hypertension; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Lifestyle and Cardiometabolic Health; and Stroke Council. Weight-Loss Strategies for Prevention and Treatment of Hypertension: A Scientific Statement From the American Heart Association. Hypertension. 2021;78(5):e38-e50. DOI:10.1161/HYP.0000000000000202.

17. Shirai K, Tanaka M, Fujita T, et al. Reduction of Excessive Visceral Fat and Safety with 52-Week Administration of Lipase Inhibitor Orlistat in Japanese: Long-Term Clinical Study. Adv Ther. 2019;36(1):217-31. DOI:10.1007/s12325-018-0822-x.

18. Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27(1):155-61. DOI:10.2337/diacare.27.1.155.

19. Yanovski SZ, Yanovski JA. Long-term drug treatment for obesity: a systematic and clinical review. JAMA. 2014;311(1):74-86. DOI:10.1001/jama.2013.281361.

20. Ardissino M, Vincent M, Hines O, et al. Long-term cardiovascular outcomes after orlistat therapy in patients with obesity: a nationwide, propensity-score matched cohort study. Eur Heart J Cardiovasc Pharmacother. 2022;8(2):179-86. DOI:10.1093/ehjcvp/pvaa133.

21. Zhou J, Massey S, Story D, Li L. Metformin: An Old Drug with New Applications. Int J Mol Sci. 2018;19(10):2863. DOI:10.3390/ijms19102863.

22. Diabetes Prevention Program Research Group. Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care. 2012;35(4):731-7. DOI:10.2337/dc11-1299.

23. Cwynar-Zając Ł. Metformin — a new approach. Pediatr Endocrinol Diabetes Metab 2021;27(2):134-40. DOI:10.5114/pedm.2021.107166.

24. Morais T, Seabra AL, Patrício BG, et al. Visceral Adipose Tissue Displays Unique Metabolomic Fingerprints in Obesity, Pre-Diabetes and Type 2 Diabetes. Int J Mol Sci. 2021;22(11):5695. DOI:10.3390/ijms22115695.

25. Tokubuchi I, Tajiri Y, Iwata S, et al. Beneficial effects of metformin on energy metabolism and visceral fat volume through a possible mechanism of fatty acid oxidation in human subjects and rats. PLoS One. 2017;12(2):e0171293. DOI:10.1371/journal.pone.0171293.

26. Seifarth C, Schehler B, Schneider HJ. Effectiveness of metformin on weight loss in non-diabetic individuals with obesity. Exp Clin Endocrinol Diabetes. 2013;121(1):27-31. DOI:10.1055/s-0032-1327734.

27. Aguilar D, Chan W, Bozkurt B, et al. Metformin use and mortality in ambulatory patients with diabetes and heart failure. Circ Heart Fail. 2011;4(1):53-8. DOI:10.1161/CIRCHEARTFAILURE.110.952556.

28. American Diabetes Association. Prevention or delay of type 2 diabetes: Standards of medical care in diabetes-2021. Diabetes Care. 2021;44(Suppl 1):S34-S39. DOI:10.2337/dc21-S003.

29. Li T, Providencia R, Jiang W, et al. Association of Metformin with the Mortality and Incidence of Cardiovascular Events in Patients with Pre-existing Cardiovascular Diseases. Drugs. 2022;82(3):311-22. DOI:10.1007/s40265-021-01665-0.

30. Campbell JM, Bellman SM, Stephenson MD, Lisy K. Metformin reduces all-cause mortality and diseases of ageing independent of its effect on diabetes control: A systematic review and meta-analysis. Ageing Res Rev. 2017;40:31-44. DOI:10.1016/j.arr.2017.08.003.

31. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854-65.

32. Roussel R, Travert F, Pasquet B, et al.; Reduction of Atherothrombosis for Continued Health (REACH) Registry Investigators. Metformin use and mortality among patients with diabetes and atherothrombosis. Arch Intern Med. 2010;170(21):1892-9. DOI:10.1001/archinternmed.2010.409.

33. Bergmark BA, Bhatt DL, McGuire DK, et al.; SAVOR-TIMI 53 Steering Committee and Investigators. Metformin Use and Clinical Outcomes Among Patients With Diabetes Mellitus With or Without Heart Failure or Kidney Dysfunction: Observations From the SAVOR-TIMI 53 Trial. Circulation. 2019;140(12):1004-14. DOI:10.1161/CIRCULATIONAHA.119.040144.

34. Idrees Z, Cancarevic I, Huang L. FDA-Approved Pharmacotherapy for Weight Loss Over the Last Decade. Cureus. 2022;14(9):e29262. DOI:10.7759/cureus.29262.

35. Papamargaritis D, le Roux CW, Holst JJ, Davies MJ. New therapies for obesity. Cardiovasc Res. 2024;119(18):2825-42. DOI:10.1093/cvr/cvac176.

36. Moiz A, Levett JY, Filion KB, et al. Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Am J Cardiol. 2024;222:121-30. DOI:10.1016/j.amjcard.2024.04.041.

37. le Roux CW, Astrup A, Fujioka K, et al; SCALE Obesity Prediabetes NN8022-1839 Study Group. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet. 2017;389(10077):1399-409. DOI:10. 1016/S0140-6736(17)30069-7.

38. Bergmann NC, Davies MJ, Lingvay I, Knop FK. Semaglutide for the treatment of overweight and obesity: A review. Diabetes Obes Metab. 2023;25(1):18-35. DOI:10.1111/dom.14863.

39. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al.; SELECT Trial Investigators. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221-32. DOI:10.1056/NEJMoa2307563.

40. Marso SP, Daniels GH, Brown-Frandsen K, et al.; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375(4):311-22. DOI:10.1056/NEJMoa1603827.

41. Arbel R, Hammerman A, Azuri J. Usefulness of Empagliflozin Versus Liraglutide for Prevention of Cardiovascular Mortality. Am J Cardiol. 2018;122(6):981-4. DOI:10.1016/j.amjcard.2018.06.010.

42. Marx N, Federici M, Schütt K, et al.; ESC Scientific Document Group. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes: Developed by the task force on the management of cardiovascular disease in patients with diabetes of the European Society of Cardiology (ESC). Eur Heart J. 2023;44(39):4043-140. DOI:10.1093/eurheartj/ehad192.

43. Jamaly S, Carlsson L, Peltonen M, et al. Surgical obesity treatment and the risk of heart failure. Eur Heart J. 2019;40(26):2131-8. DOI:10.1093/eurheartj/ehz295.

44. Schiavon CA, Cavalcanti AB, Oliveira JD, et al. Randomized Trial of Effect of Bariatric Surgery on Blood Pressure After 5 Years. J Am Coll Cardiol. 2024;83(6):637-48. DOI:10.1016/j.jacc.2023.11.032.

45. Sjöström L, Narbro K, Sjöström CD, et al.; Swedish Obese Subjects Study. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med. 2007;357(8):741-52. DOI:10.1056/NEJMoa066254.

46. Moussa O, Ardissino M, Heaton T, et al. Effect of bariatric surgery on long-term cardiovascular outcomes: a nationwide nested cohort study. Eur Heart J. 2020;41(28):2660-7. DOI:10.1093/eurheartj/ehaa069.

47. Stenberg E, Cao Y, Jernberg T, Näslund E. Major cardiovascular events after metabolic surgery in patients with previous heart disease with or without type 2 diabetes: a nationwide cohort study. Surgery for Obesity and Related Diseases 2022;18(7):935-42. DOI:10.1016/j.soard.2022.04.005.

48. Eliasson B, Liakopoulos V, Franzen S, et al. Cardiovascular disease and mortality in patients with type 2 diabetes after bariatric surgery in Sweden: a nationwide, matched, observational cohort study. Lancet Diabetes Endocrinol. 2015;3(11):847-54. DOI:10.1016/S2213-8587(15)0033449.

49. Berk KA, Borgeraas H, Narverud I, et al. Diferential efects of bariatric surgery and lifestyle interventions on plasma levels of Lp(a) and fatty acids. Lipids Health Dis. 2022;21(1):145. DOI:10.1186/s12944-022-01756-1.50.

50. Dahlberg K, Jaensson M, Cao Y, et al. Incidence of self-harm after bariatric surgery: A nationwide registry-based matched cohort study. Clin Obes. 2023;13(3):e12576. DOI:10.1111/cob.1257.